Bonus Biogroup

Bonus Biogroup ROE

The Return on Equity (ROE) of Bonus Biogroup (BONS.TA) as of Nov 4, 2026 is 432.38 %. In the previous year, Return on Equity (ROE) was -399.97 % — a change of -208.10% (higher).

ROE

432.38 %

YoY

-208.10%

Last updated:

In 2025, Bonus Biogroup's return on equity (ROE) was 432.38 %, a -208.10% increase from the -399.97 % ROE in the previous year.

The Bonus Biogroup ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
589.71 ILS
Jan 1, 2019
162.09 ILS
Jan 1, 2020
-71.77 ILS
Jan 1, 2021
-106.69 ILS
Jan 1, 2022
-68.64 ILS
Jan 1, 2023
-97.35 ILS
Jan 1, 2024
-399.97 ILS
Jan 1, 2025
432.38 ILS
The Bonus Biogroup ROE history
YEARROEYoY
432.38 %-208.10%
-399.97 %+310.85%
-97.35 %+41.84%
-68.64 %-35.67%
-106.69 %+48.66%
-71.77 %-144.28%
162.09 %-72.51%
589.71 %+86.40%
316.37 %+45.17%
217.93 %-77.51%
968.97 %-152.22%
-1,855.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

ROE Details

Decoding Bonus Biogroup's Return on Equity (ROE)

Bonus Biogroup's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Bonus Biogroup's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Bonus Biogroup's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Bonus Biogroup’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Bonus Biogroup stock

Return on Equity (ROE) of Bonus Biogroup is 432.38 % in 2025.

Return on Equity (ROE) of Bonus Biogroup changed from -399.97 % to 432.38 %, representing a -208.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Bonus Biogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bonus Biogroup

All Key Metrics — Bonus Biogroup